Table 1. Baseline characteristics of the study patients according to the recurrence pattern at the time of first recurrence.
| GE cHCC-CC (n = 25) |
PE cHCC-CC (n = 17) |
HCC-control (n = 59) |
Pa | Pb | |
|---|---|---|---|---|---|
| Age, years | 54.2 ± 10.1 | 52.6 ± 8.9 | 56.2 ± 9.8 | 0.60 | 0.40 |
| Male Gender | 21 (84.0) | 16 (94.1) | 53 (89.8) | 0.37 | 0.29 |
| Aetiology | 0.49 | 0.20 | |||
| HBV | 23 (92) | 17 (100) | 50 (84.7) | ||
| HCV | 0 (0) | 0 (0) | 4 (6.8) | ||
| Alcohol | 1 (4) | 0 (0) | 0 (0) | ||
| Others | 1 (4) | 0 (0) | 5 (8.5) | ||
| Liver cirrhosis | 14 (56) | 8 (47.1) | 32 (54.2) | 0.57 | 0.88 |
| Child-Pugh class A | 25 (100) | 17 (100) | 56 (94.9) | > 0.99 | 0.55 |
| Initial enhancement pattern | 0.04 | 0.01 | |||
| Global enhancement | 14 (56) | 4 (23.5) | 49 (83.1) | ||
| Peripheral enhancement | 11 (44) | 13 (76.5) | 10 (16.9) | ||
| Size, cm | 3.5 (2.2–9.3) | 5.5 (3.6–7.5) | 5.0 (3.5–7.5) | 0.88 | 0.90 |
| Multiple tumors (≥2) | 4 (16) | 4 (23.5) | 14 (23.7) | 0.69 | 0.57 |
| Gross vascular invasion | 3 (12) | 1 (5.9) | 7 (11.9) | 0.64 | > 0.99 |
| 7th AJCC stage | 0.86 | – | |||
| I | 17 (68) | 12 (70.6) | 46 (73) | ||
| II | 8 (32) | 5 (29.4) | 6 (9.5) | ||
| III | 0 (0) | 0 (0) | 11 (17.5) | ||
| Combined/mixed histology | 24 (96) / 1 (4) | 14 (82.4) / 3 (17.6) | – | 0.29 | – |
| AFP, ng/mL | 36 (9.8–642.5) | 9.7 (5.3–939.5) | 50 (7.5–743) | 0.40 | 0.31 |
| CA 19–9, U/mL | 18.4 (13.9–39.8) | 25.2 (7.6–168.8) | 14.4 (7.7–18.2) | 0.82 | 0.03 |
Data presented as mean and standard deviation (SD) or median and IQR (interquartile range) or frequency (n) and percentage where appropriate.
a, between GE cHCC-CC and PE cHCC-CC
b, between GE cHCC-CC and HCC-control.
GE, globally enhancing; cHCC-CC, combined hepatocellular-cholangiocarcinoma; PE, peripherally enhancing; HBV, hepatitis B virus; HCV, hepatitis C virus; AJCC, American Joint Committee on Cancer system; AFP, α-feto protein; CA, carbohydrate antigen.